The future of glaucoma will likely not resemble the current state of management of the disease, with numerous advances on the horizon, according to Harry Quigley MD, the A.
A team of researchers have conducted a study bringing the connection between statin use and the risk of primary open-angle glaucoma (POAG) into sharper focus.
Ironically, though IOP drugs are markedly effective at decreasing the development and progression of open-angle glaucoma, compliance is “notoriously poor” among aging patients for a few reasons, said
Use of statins to control elevated cholesterol levels and prevent cardiovascular events also has another upside, i.e., a concomitant lower risk of development of primary open-angle glaucoma (POAG).
Exfoliation glaucoma (XFG), the second most commonly occurring glaucoma after primary open-angle glaucoma (POAG), is a more challenging pathology to treat for a number of reasons.
Findings from a prospective study conducted at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, demonstrate the feasibility of creating an automated re
Reviewed by Wallace L.M. Alward, MD
Yvonne Buys, MD, says ophthalmologists can choose from a range of the latest devices for measuring IOP, each with its own strengths and weaknesses. While new technology continues to emerge, Dr. Buys provides an overview of tonometer technology.
The use of eye drops as a treatment for glaucoma will likely become rare considering the pace of progress in developing alternative drug delivery systems, said James D. Brandt, MD, to attendees of the 2018 Glaucoma Subspecialty Day.